MyOme key facts
as of Oct 2026- Developer of a genetic testing technology designed to provide comprehensive health insights through whole genome sequencing.
- MyOme is valued at approximately $186.5M as of Oct 2026 (last reported valuation).
- It has raised $99.9M; the latest was Later Stage VC ($63.5M) in Dec 2025.
- Notable investors include Sequoia Capital, Founders Fund, Samsung NEXT Ventures, Norwest, HOF Capital — 13 tracked in total.
- Status: Privately Held (backing).
MyOme's last reported valuation, Dec 2025. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch MyOme: the Monday email on marks, rounds and moves
MyOme funding rounds
No funding rounds for MyOme are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs MyOme
13+MyOme valuation
MyOme's last reported valuation was $187 million in Dec 2025. No priced round, secondary trade or fund mark has surfaced since.
MyOme investors
13 investors are on record for MyOme, including Sequoia Capital, Founders Fund, Samsung NEXT Ventures and Norwest. By type, the record holds 6 venture capital firms.
About MyOme
Developer of a genetic testing technology designed to provide comprehensive health insights through whole genome sequencing. The company's platform offers detailed reports on disease risk and medication response, includes independent physician reviews and genetic counselling, and utilizes advanced technologies to ensure ongoing updates, enabling individuals to make informed health decisions throughout their lives while maintaining data privacy and security.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2017
- Employees
- 48
- Website
- myome.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.